Sintilimab blood levels in advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how the amount of Sintilimab in your blood relates to how well it works and what side effects you might have. If you have advanced stomach cancer and are planning to get Sintilimab, this trial could help your doctor find the best dose for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma of the stomach or where the stomach meets the esophagus.
- You plan to receive treatment with the drug Sintilimab (a type of immunotherapy).
- Your current health status allows you to be up and active at least half the day (ECOG score 0 to 2).
- Your doctor expects you to live at least 3 more months.
- You are willing and able to follow the treatment plan and come to appointments.
- You agree to join the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiotherapy can help people aged 75 or older with locally advanced stomach cancer. It aims to shrink tumors and improve outcomes.
This trial tests a combination of three drugs (sintilimab, ramucirumab, and paclitaxel) for people with stomach cancer that returned soon after finishing initial chemotherapy. The goal is to see if this combination can help control the cancer and improve outcomes.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
This trial tests whether the immunotherapy drug Sintilimab can help prevent esophageal cancer from returning after standard chemotherapy and radiation. It is for patients aged 70-85 who cannot have or choose not to have surgery.
This trial tests a combination of two medicines (sintilimab and FOLFIRI) as a second option for people with advanced stomach cancer that no longer responds to first treatment. It aims to see if this combination can help control the cancer.
Hear when a new Gastric (Cardia, Body) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.